Factsheet: September 2022
The Fund's objective is to achieve optimal long-term capital growth through active management of a portfolio of large-capitalisation stocks based primarily in North America.
The investment strategy is based on fundamental analysis. The stock selection process is based in particular on the activities of the companies, their governance, financial structure and development perspectives. The fund aims above all to identify companies with dominant positions, with a significant reinvestment capacity and low levels of gearing.
The recommended investment period is 5 years. The reference currency is the US Dollar.
Persistent inflation and an ever-tougher rhetoric from the FED, led the American markets to experience a further decline in September, with, for the concerned period (31.08.2022 to 28.09.2022) -5.97% for the S&P 500 index, -5.80% for the Dow Jones index, and -6.34% for the NASDAQ 100.
The biotech sector was up 1.62%, during the month, while the Steel sector was down -19.52%.
The FFM American Growth Fund was down for the relevant period (31.08.2022 to 28.09.2022) by -7.52%.
Despite their loss, the three best holdings were Stryker (-0.96%), PepsiCo (-4.60%), and Idexx Laboratories (-6.28%). Technology suffered the worst performance with Adobe (-26.31%) and Meta (-16.72%). The North American railroad transporter, CSX, lost -15.83%.
Disclaimer: Past performance is not a reliable indicator of future performance and in no way constitutes a guarantee of future performance or capital. This non-contractual document is for information purposes only and does not constitute an offer for sale.
Prior to any investment, we recommend that you consult your advisor for a better understanding of risks. In the event of disagreement or litigation arising from this document, the full prospectus will prevail.
For more information, please email us: email@example.com